PMC:7253235 / 31485-32766 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T71","span":{"begin":72,"end":76},"obj":"Body_part"},{"id":"T72","span":{"begin":94,"end":102},"obj":"Body_part"},{"id":"T73","span":{"begin":150,"end":158},"obj":"Body_part"},{"id":"T74","span":{"begin":320,"end":328},"obj":"Body_part"},{"id":"T75","span":{"begin":380,"end":384},"obj":"Body_part"},{"id":"T76","span":{"begin":655,"end":663},"obj":"Body_part"},{"id":"T77","span":{"begin":720,"end":725},"obj":"Body_part"},{"id":"T78","span":{"begin":842,"end":846},"obj":"Body_part"},{"id":"T79","span":{"begin":1097,"end":1105},"obj":"Body_part"}],"attributes":[{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"An adverse effect that can occur with either anti-PD-1 therapy or CAR-T cell therapy involves cytokine release syndrome (CRS) which is similar to the cytokine storm phenomenon that occurs in patients with severe COVID-19 [80, 82, 83]. CRS occurs as a result of hyperimmune activation in response to tumor death, whereas cytokine storm in COVID-19 patients occurs as a result of T cell hyperactivation from immune dysregulation [80, 84]. Similar markers are elevated in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of which IL-6 has also been shown to be a mortality predictor in COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that develop cytokine storm syndrome are at risk of developing ARDS and multi-organ failure [84, 85]. Immunosuppression with tocilizumab, an IL-6 inhibitor, is used to treat CRS associated with CAR-T cell therapy [80, 86]. Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]. Moreover, the cytokine storm observed with COVID-19 has also been noted to be similar to that of secondary hemophagocytic lymphohistiocytosis (HLH) which is also treated with immunosuppression [64]."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T41","span":{"begin":720,"end":725},"obj":"Body_part"}],"attributes":[{"id":"A41","pred":"uberon_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"An adverse effect that can occur with either anti-PD-1 therapy or CAR-T cell therapy involves cytokine release syndrome (CRS) which is similar to the cytokine storm phenomenon that occurs in patients with severe COVID-19 [80, 82, 83]. CRS occurs as a result of hyperimmune activation in response to tumor death, whereas cytokine storm in COVID-19 patients occurs as a result of T cell hyperactivation from immune dysregulation [80, 84]. Similar markers are elevated in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of which IL-6 has also been shown to be a mortality predictor in COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that develop cytokine storm syndrome are at risk of developing ARDS and multi-organ failure [84, 85]. Immunosuppression with tocilizumab, an IL-6 inhibitor, is used to treat CRS associated with CAR-T cell therapy [80, 86]. Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]. Moreover, the cytokine storm observed with COVID-19 has also been noted to be similar to that of secondary hemophagocytic lymphohistiocytosis (HLH) which is also treated with immunosuppression [64]."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T237","span":{"begin":66,"end":69},"obj":"http://purl.obolibrary.org/obo/CLO_0002199"},{"id":"T238","span":{"begin":70,"end":76},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T239","span":{"begin":249,"end":250},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T240","span":{"begin":273,"end":283},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T241","span":{"begin":366,"end":367},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T242","span":{"begin":378,"end":384},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T243","span":{"begin":537,"end":540},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T244","span":{"begin":563,"end":564},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T245","span":{"begin":607,"end":609},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T246","span":{"begin":720,"end":725},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T247","span":{"begin":836,"end":839},"obj":"http://purl.obolibrary.org/obo/CLO_0002199"},{"id":"T248","span":{"begin":840,"end":846},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T249","span":{"begin":1038,"end":1039},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T250","span":{"begin":1062,"end":1072},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T251","span":{"begin":1135,"end":1138},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"An adverse effect that can occur with either anti-PD-1 therapy or CAR-T cell therapy involves cytokine release syndrome (CRS) which is similar to the cytokine storm phenomenon that occurs in patients with severe COVID-19 [80, 82, 83]. CRS occurs as a result of hyperimmune activation in response to tumor death, whereas cytokine storm in COVID-19 patients occurs as a result of T cell hyperactivation from immune dysregulation [80, 84]. Similar markers are elevated in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of which IL-6 has also been shown to be a mortality predictor in COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that develop cytokine storm syndrome are at risk of developing ARDS and multi-organ failure [84, 85]. Immunosuppression with tocilizumab, an IL-6 inhibitor, is used to treat CRS associated with CAR-T cell therapy [80, 86]. Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]. Moreover, the cytokine storm observed with COVID-19 has also been noted to be similar to that of secondary hemophagocytic lymphohistiocytosis (HLH) which is also treated with immunosuppression [64]."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T76","span":{"begin":50,"end":52},"obj":"Chemical"},{"id":"T77","span":{"begin":495,"end":497},"obj":"Chemical"},{"id":"T79","span":{"begin":505,"end":510},"obj":"Chemical"},{"id":"T80","span":{"begin":532,"end":534},"obj":"Chemical"},{"id":"T82","span":{"begin":767,"end":778},"obj":"Chemical"},{"id":"T83","span":{"begin":783,"end":785},"obj":"Chemical"},{"id":"T85","span":{"begin":788,"end":797},"obj":"Chemical"},{"id":"T86","span":{"begin":879,"end":890},"obj":"Chemical"},{"id":"T87","span":{"begin":969,"end":971},"obj":"Chemical"},{"id":"T88","span":{"begin":974,"end":984},"obj":"Chemical"},{"id":"T89","span":{"begin":1008,"end":1016},"obj":"Chemical"}],"attributes":[{"id":"A76","pred":"chebi_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A77","pred":"chebi_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A78","pred":"chebi_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A81","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A84","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"}],"text":"An adverse effect that can occur with either anti-PD-1 therapy or CAR-T cell therapy involves cytokine release syndrome (CRS) which is similar to the cytokine storm phenomenon that occurs in patients with severe COVID-19 [80, 82, 83]. CRS occurs as a result of hyperimmune activation in response to tumor death, whereas cytokine storm in COVID-19 patients occurs as a result of T cell hyperactivation from immune dysregulation [80, 84]. Similar markers are elevated in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of which IL-6 has also been shown to be a mortality predictor in COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that develop cytokine storm syndrome are at risk of developing ARDS and multi-organ failure [84, 85]. Immunosuppression with tocilizumab, an IL-6 inhibitor, is used to treat CRS associated with CAR-T cell therapy [80, 86]. Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]. Moreover, the cytokine storm observed with COVID-19 has also been noted to be similar to that of secondary hemophagocytic lymphohistiocytosis (HLH) which is also treated with immunosuppression [64]."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T173","span":{"begin":94,"end":119},"obj":"Phenotype"},{"id":"T174","span":{"begin":150,"end":164},"obj":"Phenotype"},{"id":"T175","span":{"begin":299,"end":304},"obj":"Phenotype"},{"id":"T176","span":{"begin":320,"end":334},"obj":"Phenotype"},{"id":"T177","span":{"begin":406,"end":426},"obj":"Phenotype"},{"id":"T178","span":{"begin":655,"end":669},"obj":"Phenotype"},{"id":"T179","span":{"begin":1097,"end":1111},"obj":"Phenotype"}],"attributes":[{"id":"A173","pred":"hp_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A174","pred":"hp_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A175","pred":"hp_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A176","pred":"hp_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A177","pred":"hp_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A178","pred":"hp_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A179","pred":"hp_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"An adverse effect that can occur with either anti-PD-1 therapy or CAR-T cell therapy involves cytokine release syndrome (CRS) which is similar to the cytokine storm phenomenon that occurs in patients with severe COVID-19 [80, 82, 83]. CRS occurs as a result of hyperimmune activation in response to tumor death, whereas cytokine storm in COVID-19 patients occurs as a result of T cell hyperactivation from immune dysregulation [80, 84]. Similar markers are elevated in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of which IL-6 has also been shown to be a mortality predictor in COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that develop cytokine storm syndrome are at risk of developing ARDS and multi-organ failure [84, 85]. Immunosuppression with tocilizumab, an IL-6 inhibitor, is used to treat CRS associated with CAR-T cell therapy [80, 86]. Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]. Moreover, the cytokine storm observed with COVID-19 has also been noted to be similar to that of secondary hemophagocytic lymphohistiocytosis (HLH) which is also treated with immunosuppression [64]."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T201","span":{"begin":0,"end":234},"obj":"Sentence"},{"id":"T202","span":{"begin":235,"end":436},"obj":"Sentence"},{"id":"T203","span":{"begin":437,"end":623},"obj":"Sentence"},{"id":"T204","span":{"begin":624,"end":743},"obj":"Sentence"},{"id":"T205","span":{"begin":744,"end":864},"obj":"Sentence"},{"id":"T206","span":{"begin":865,"end":1082},"obj":"Sentence"},{"id":"T207","span":{"begin":1083,"end":1281},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"An adverse effect that can occur with either anti-PD-1 therapy or CAR-T cell therapy involves cytokine release syndrome (CRS) which is similar to the cytokine storm phenomenon that occurs in patients with severe COVID-19 [80, 82, 83]. CRS occurs as a result of hyperimmune activation in response to tumor death, whereas cytokine storm in COVID-19 patients occurs as a result of T cell hyperactivation from immune dysregulation [80, 84]. Similar markers are elevated in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of which IL-6 has also been shown to be a mortality predictor in COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that develop cytokine storm syndrome are at risk of developing ARDS and multi-organ failure [84, 85]. Immunosuppression with tocilizumab, an IL-6 inhibitor, is used to treat CRS associated with CAR-T cell therapy [80, 86]. Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]. Moreover, the cytokine storm observed with COVID-19 has also been noted to be similar to that of secondary hemophagocytic lymphohistiocytosis (HLH) which is also treated with immunosuppression [64]."}

2_test

{"project":"2_test","denotations":[{"id":"32462289-32212881-24380971","span":{"begin":222,"end":224},"obj":"32212881"},{"id":"32462289-28880983-24380972","span":{"begin":226,"end":228},"obj":"28880983"},{"id":"32462289-32212881-24380973","span":{"begin":428,"end":430},"obj":"32212881"},{"id":"32462289-32114747-24380974","span":{"begin":432,"end":434},"obj":"32114747"},{"id":"32462289-32192578-24380975","span":{"begin":611,"end":613},"obj":"32192578"},{"id":"32462289-32212881-24380976","span":{"begin":615,"end":617},"obj":"32212881"},{"id":"32462289-32114747-24380977","span":{"begin":619,"end":621},"obj":"32114747"},{"id":"32462289-32114747-24380978","span":{"begin":735,"end":737},"obj":"32114747"},{"id":"32462289-32212881-24380979","span":{"begin":856,"end":858},"obj":"32212881"},{"id":"32462289-29622697-24380980","span":{"begin":860,"end":862},"obj":"29622697"},{"id":"32462289-32212881-24380981","span":{"begin":1074,"end":1076},"obj":"32212881"},{"id":"32462289-29207939-24380982","span":{"begin":1078,"end":1080},"obj":"29207939"},{"id":"32462289-32192578-24380983","span":{"begin":1277,"end":1279},"obj":"32192578"}],"text":"An adverse effect that can occur with either anti-PD-1 therapy or CAR-T cell therapy involves cytokine release syndrome (CRS) which is similar to the cytokine storm phenomenon that occurs in patients with severe COVID-19 [80, 82, 83]. CRS occurs as a result of hyperimmune activation in response to tumor death, whereas cytokine storm in COVID-19 patients occurs as a result of T cell hyperactivation from immune dysregulation [80, 84]. Similar markers are elevated in both phenomena, including IL-6, TNF-alpha, and IFN-λ, of which IL-6 has also been shown to be a mortality predictor in COVID-19 patients [27, 64, 80, 84]. COVID-19 patients that develop cytokine storm syndrome are at risk of developing ARDS and multi-organ failure [84, 85]. Immunosuppression with tocilizumab, an IL-6 inhibitor, is used to treat CRS associated with CAR-T cell therapy [80, 86]. Additionally, tocilizumab immunosuppression is used to treat immune-related adverse events (irAEs) from PD-1 inhibitors that are refractory to steroids; irAEs also occur as a result of hyperimmune activation [80, 87]. Moreover, the cytokine storm observed with COVID-19 has also been noted to be similar to that of secondary hemophagocytic lymphohistiocytosis (HLH) which is also treated with immunosuppression [64]."}

PMC:7253235 / 31485-32766 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7253235 / 31485-32766 JSON TXT